We observe that oral exposure to deltamethrin resulted in significant modulation of insulin response and lipid metabolism in the liver, in line with our prior report and highlighting impacts to metabolism that may shape metabolic syndrome (White et al., 2025). This evidence concerns the gene INS and metabolic syndrome.